Indutrade ABOMXSTO: INDT

Indutrade acquires diagnostic imaging specialist Euromed in Poland

· Issued by Indutrade AB

Summary by 6ix AI

Indutrade has agreed to acquire Euromed, a technical trading company in Poznań, Poland, that specialises in diagnostic imaging equipment, mainly ultrasound systems, for healthcare and veterinary use. Closing depends on approval by the Polish competition authority.

Key details

  • Euromed also offers fetal monitoring, digital X-ray and mobile CT (computed tomography) scanning solutions. Its customers include public and private hospitals, healthcare providers and insurance companies.
  • Euromed was founded in 2005 and has 40 employees.
  • Euromed will become part of Indutrade's Business Area Life Science.
  • This is Indutrade's eleventh acquisition in 2026. Indutrade expects it to have a marginally positive impact on its earnings per share.

What’s still pending

  • Closing requires approval by the Polish competition authority.
  • Closing is expected during the fourth quarter of 2026.

6ix AI wrote this summary from the release below and checked it against the release.

Euromed is a technical trading company specialised in diagnostic imaging equipment, primarily ultrasound systems, for healthcare and veterinary applications. The product offering is complemented by fetal monitoring, digital X-ray and mobile CT solutions. The company has a diverse customer base, including public and private hospitals, healthcare providers and insurance companies. Euromed was founded in 2005, has 40 employees and is located in Poznań, Poland.

"Euromed is a high-quality company with strong long-term partnerships, high technical expertise and an offering that fits well within Indutrade. We are happy to welcome Euromed and the team to Indutrade, further strengthening our presence in Poland", said Bo Annvik, President and CEO of Indutrade.

Closing is conditional upon approval by the Polish competition authority and is expected to be finalised during Q4 2026. Euromed will be included in Indutrade's Business Area Life Science. The acquisition is Indutrade's eleventh in 2026 and is expected to have a marginally positive impact on Indutrade's earnings per share.

Indutrade AB on 6ix

Earlier from Indutrade

All Indutrade news releases